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Background
With the introduction of dual-modality PET/CT imaging,
the nuclear medicine community is witnessing a revolution
in its daily clinical practice. The hope is that this
technology will alleviate the complexity of the clinical
decision-making process and improve patient management
[1]. Even though combined PET/CT units have been
accepted commercially, the clinical benefits of and the
need for these systems remain controversial [2] and are still
being debated [3]. For example, PET alone provides
enough information to resolve clinically relevant metabolic
problems for many malignant diseases, offering a sensitiv-
ity and specificity in excess of 90%; some argue that an
incremental improvement in specificity or sensitivity
beyond that point probably cannot justify the cost of
performing image fusion systematically for all patients on
a routine basis. The marketing strategy of vendors
(supported by many scientists) aiming to achieve wider
diffusion of hybrid PET/CT technology in clinical practice
is that the added value of combined units is well established
and represents the ultimate solution for image co-registra-
tion, allowing appropriate combination of imaging technol-
ogies to yield useful fusion of functional and anatomical
images [1]. It appears that more than 90% of last year’s
PET sales were PET/CT; this is leading almost all scanner
manufacturers to entirely replace PET-only scanners by
combined PET/CT, a questionable choice according to
some active researchers in the field [2]. Whereas combined
PET/CT has many interesting features and offers many
advantages compared with software approaches to image
co-registration for patient diagnosis and image-guided
radiation therapy, it is often argued that combined PET/
CT is not the ultimate solution for image co-registration and
will most likely not be considered a major breakthrough
that revolutionised the paradigm of medical imaging [3].
It is the role of medical physicists providing physics support
to clinical PET facilities and involved in today’s biomedical
imaging research enterprise to debate important issues related
to design aspects of this technology and optimal data
acquisition and processing protocols with the aim of improv-
ing image quality and obtaining accurate quantitative mea-
sures. Among many other issues, the important role of
attenuation correction (AC) in PET has been discussed in a
number of review papers [4–6] and debated in editorials [7, 8]
and point/counterpoint papers [9–11].
Clinical significance of attenuation correction
There is no doubt that incorporation of AC in PET data
processing protocols contributes in improving image quality,
interpretive certainty and diagnostic accuracy. The extent to
which it can be shown to have a decisive impact upon the
goal for which the image is to be utilised is a much more
tricky issue, as very few studies have addressed the clinical
consequences for reporting. For example, it was reported
that AC in myocardial perfusion imaging instigated a change
in diagnosis in approximately 10% of patients,
corresponding to one-fifth of the abnormal studies [12].
Nevertheless, the added value provided by AC is no longer
the subject of debate in myocardial perfusion imaging [13]
or even in oncology studies, where it remained controver-
sial [7, 14, 15] until it was shown fairly conclusively that
AC almost always facilitates tumour detection [16].
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Functional brain imaging can be regarded as a special case
since many simple and sophisticated transmissionless AC
methods can be used; as a consequence it would be
irrational to attempt to justify the use of non-corrected
images even in a busy clinical department or in facilities
lacking expert physics support [17]. Whether the use of
sophisticated transmission-based methods is required in
daily practice or justified only in research studies, where
there is greater emphasis on accurate quantitative measure-
ments, is another issue that is still being debated [9–11].
Pros and cons of radionuclide transmission-based
attenuation correction
Before the advent of combined PET/CT units, measured
AC using external positron-emitting (68Ge/68Ga) or single-
photon emitting (137Cs) radionuclide sources was the most
commonly used procedure (gold standard) in both clinical
and research settings. Transmission-based scanning is
expected to yield the best attenuation map as a result of
matched energy and spatial resolution. Scaling for the
difference between 662-keV (for 137Cs sources) and 511-
keV energies is less of an issue compared with scaling low-
energy polyenergetic X-ray beams for CT and can be easily
performed by normalisation to a slab phantom scan and
correction for scatter and cross-section variation using a
log-linear transformation of the attenuation factors [18].
Single-photon emitting transmission sources have the
further advantage that, in order to reduce the interference,
radionuclides can be chosen that emit photons at an energy
different from the 511 keV of annihilation photons. Various
strategies have also been proposed to eliminate contamina-
tion of emission data by transmission photons (for
simultaneous scanning) and to reduce spillover of emission
data into the transmission energy window (for post-
injection transmission scanning) [5]. For example, combin-
ing non-uniform emission contamination subtraction with
transmission image segmentation was proven to success-
fully compensate for emission contamination in transmis-
sion measurements on the high-resolution research
tomograph (HRRT) PET scanner [19]. Furthermore, substan-
tial reduction of emission data contamination by transmis-
sion photons, allowing achievement of good transmission
image quality, was reported on a prototype simultaneous
emission–transmission scanning system [20] through the use
of a fast, dedicated, lutetium oxyorthosilicate-based refer-
ence detector placed close to the collimated coincidence
point source used to produce the transmission data.
The most important drawbacks of radionuclide transmis-
sion scanning are the extra complexity of the PET camera
design and the data acquisition and processing protocols
and the extra cost resulting from the periodic requirement to
replace expensive sources. Other known limitations already
observed during the early stages of PET development
include registration problems caused by patient- or motion-
induced misalignment between transmission and emission
scans, which can result in erroneous estimation of regional
tissue activity concentrations, noise propagation from the
transmission scan to the emission scan [21], particularly for
lines of response that pass through the thickest parts of the
body and larger bony structures, and the time required to
perform a statistically reliable transmission scan. The
filtering of transmission scans aiming at noise reduction
results in a difference in spatial resolution between the
transmission and the emission data to which it is applied
since emission data are not usually smoothed at this stage.
This causes bias at the interfaces between regions of high
and low tissue density [22] and is a far greater challenge in
whole-body PET owing to the more complex juxtapositions
of media with different attenuating properties, e.g. lung/soft
tissue/bone in the thorax. This can be tackled by using more
sophisticated approaches such as anisotropic diffusion
filtering [23]. To avoid lengthy transmission scans, tech-
niques using transmission image segmentation and tissue
classification have been proposed to reduce noise propaga-
tion from transmission to emission scans by delineating
different anatomical regions of uniform attenuation fol-
lowed by assignment of known tissue-dependent attenua-
tion coefficients using weighted averaging. The adverse
effect is the increased bias introduced by segmented AC
when assessing absolute or semi-quantitative indices, the
magnitude of which is difficult to predict in clinical studies.
One should note that, except the registration problem, most
of these limitations have been overcome through research,
with the development of rod-windowed transmission
devices, reliable simultaneous and post-injection transmis-
sion scanning methodology and robust transmission image
segmentation algorithms [5].
Pros and cons of CT-based attenuation correction
Dual-modality imaging offers a critical advantage over
separate PET and CT imaging units in correlating functional
and anatomical images without moving the patient (other
than table translation). The use of CT also generates a high-
resolution noise-free attenuation map, allowing noise
propagation to PET emission data to be reduced signifi-
cantly and overall scanning time to be decreased; this in
turn improves patient comfort and throughput and reduces
operating costs as there is no need for regular replacement
of transmission radionuclide sources.
Notwithstanding the success and widespread clinical
adoption of PET/CT, there are several challenges confront-
ing the use of dual-modality imaging that may represent
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inherent limitations to this technique. In addition to a much
higher absorbed dose to the patient, there are many physical
and physiological factors that hamper the accurate registra-
tion of both imaging modalities and the accurate quantita-
tive analysis of PET data following CT-based AC (CT-AC).
These include: the inherent difference between CT and PET
image matrix size and resolution; polychromaticity of X-ray
photons (30–140 keV) requiring transformation to mono-
energetic 511-keV photons and creating beam-hardening
artefacts; misregistration between CT and PET images
owing to, for instance, respiratory motion; truncation
artefacts due to the discrepancy between fields of view in
a combined PET/CT scanner; the presence of oral and
intravenous contrast medium; metallic implants; X-ray
scatter in CT images for future generation cone-beam
geometries; and other CT artefacts from any source.
Patient motion (either voluntarily or involuntarily)
between or during the anatomical and functional image
acquisitions remains a major challenge for PET/CT imaging
protocols. Patient motion also occurs due to respiration,
cardiac motion, peristalsis and bladder filling, all of which
can lead to motion blurring or misregistration errors
between the PET and CT image acquisitions [24]. It is
frequently suggested that, owing to the different time
resolution and respiratory patterns between PET and CT
scanning, the diaphragm is displaced or occupies different
positions in the CT images (usually captured during a single
position) and the PET images (usually averaged over
several respiratory cycles). This misregistration may induce
mislocalisation of abnormalities and, more importantly,
produce incorrect AC maps leading to typical cold artefacts
on approximately 84% of studies at the lung/diaphragm
interface [25]. It has also been reported that liver metastases
not detectable on PET images obtained through CT-AC are
clearly seen on radionuclide transmission-based attenua-
tion-corrected images [26]. Even if this has been recognised
as a rare pitfall, false negative interpretation of liver dome
lesions may result from erroneous CT-AC. It has also been
reported that radionuclide scanning-based AC would be a
more reliable approach to AC for ungated cardiac PET
studies because it has similar temporal characteristics to the
PET scan, and thus provides consistent data for AC [27].
It is still a matter of controversy whether the use of
contrast medium in dual-modality PET/CT imaging pro-
duces medically significant artefacts. Some studies have
corroborated while others have contradicted the hypothesis
that the presence of contrast medium can be a source of
errors and artefacts when the CT data are used for AC of
PET images, depending on the route of administration and
the phase protocol of CT imaging [28]. The optimal quantity
and route of administration of contrast medium and
potential correction schemes are still open questions which
require further research and development efforts [29].
The progress in CT-AC methodology has been immense
in the past few years, the main opportunities having arisen
from the development of both optimised scanning protocols
and innovative and faster image processing algorithms. This
has permitted the implementation of much more ambitious
algorithms that tackle the challenges of whole-body PET/CT
imaging. Some recently proposed solutions to the aforemen-
tioned problems have now been used successfully in clinical
and research settings. These include optimised contrast-
enhanced CT protocols, tracking and correction of respiratory
motion, metal artefact reduction, truncation artefact correction,
and beam hardening and x-ray scatter compensation. It should
be pointed out that the majority of methods and algorithms
described in the literature have been applied primarily to
computer-simulated images and simplified experimental
arrangements. Some solutions to the problems associated with
AC are less suitable for routine application in patients than in
phantom simulations. These hot topics undoubtedly require
further research and development efforts.
Comparison of attenuation correction methodologies
Within the context of whole-body imaging, the problems
associated with the use of CT-AC and the complexity
inherent to transmissionless AC have spurred the further
development of transmission-based AC methodologies,
which remain an active research area. Some scanner
manufacturers have decided to preserve radionuclide trans-
mission scanning devices on new-generation hybrid PET/CT
units, such as the Sceptre P3 (Hitachi Medical Systems
America, Inc., Twinsburg, OH, USA), the Gemini (Philips
Medical Systems, Best, The Netherlands) and the first units
of the Discovery LS PET/CT series (GE Healthcare
Technologies, Waukesha, WI). This allows the combination
of both CT- and radionuclide scanning-based AC to permit
effective imaging of patients with metal implants and
prosthetics. A limited number of studies reported in the
literature have offered detailed comparative assessment
between CT-AC and radionuclide scanning-based AC,
including 68Ga versus CT-AC [27, 30–33] and 137Cs versus
CT-AC [26, 34]. Clinical and scientific data are required to
impartially establish whether the advantages and clinical
benefits of transmission scanning-based AC are sufficient
to offset its additional running costs, or whether CT-AC
should be the only option on hybrid PET/CT units.
Summary
It is undisputable that CT-AC has several virtues and should
be targeted for further research. However, it should be
recognised that its clinical benefits have not been unequiv-
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ocally demonstrated and need to be carefully documented
by investigators before wider acceptance. The key point is
that many PET procedures do not require a diagnostic
quality CT and radionuclide-based transmission scanning
would be a better option than low-dose CT protocols. It is
still too early to claim that transmission scanning devices
are obsolete for PET/CT, and that CT-AC should be the
gold standard on these systems. My opinion is that
transmission scanning still has a genuine role and remains
an appealing alternative until all the problems associated
with CT-AC are resolved through research.
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